No Data
No Data
Shandong Lukang Pharmaceutical's 2024 half-year report
Shandong Lukang Pharmaceutical 2024 Interim Report Summary
Shandong Lukang Pharmaceutical (600789.SH): Obtained pharmaceutical registration certificate and approval notice for the listing application of chemical raw materials.
On August 19th, Gelunhui reported that Shandong Lukang Pharmaceutical (600789.SH) has received the Drug Registration Certificate for moxifloxacin hydrochloride tablets issued by the National Medical Products Administration and the Approval Notice for the Listing Application of moxifloxacin hydrochloride active pharmaceutical ingredient for chemical raw materials. Moxifloxacin hydrochloride is a fourth-generation quinolone antibiotic with a bactericidal mechanism that interferes with topoisomerase II and IV.
Lukang Pharmaceutical's Unit Gets Nod to Market Adenosylcobalamin Capsules
Shandong Lukang Pharmaceutical (600789.SH): Adenosylcobalamin Capsules Obtains Pharmaceutical Registration Certificate.
Shandong Lukang Pharmaceutical (600789.SH) announced that its subsidiary, Shandong Lukang Pharmaceutical Group Sate Co., Ltd., received the Drug Registration Certificate for Adenosylcobalamin Capsules issued by the State Drug Administration. Adenosylcobalamin Capsules are mainly used for the prevention and treatment of vitamin B12 deficiency, megaloblastic anemia, neurological diseases related to malignant anemia, etc.
Earnings Not Telling The Story For Shandong Lukang Pharmaceutical Co.,Ltd. (SHSE:600789) After Shares Rise 26%
No Data